Clinical Trial Update: A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing pralsetinib to standard of care as first-line therapy for advanced RET-fusion non-small cell lung cancer was terminated, with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• GAVRETO (pralsetinib) (pralsetinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm | Phase 3 | Status: TERMINATED | Results posted: 2026-03-05